The ongoing annual meeting of the American Society of Clinical Oncology (ASCO) saw another batch of good news from drugmakers, including from US drug giant Merck & Co (NYSE: MRK), Medivation (Nasdaq: MDVN) and Astellas (TSE: 4503) and ARIAD Pharmaceuticals (Nasdaq: ARIA), as well as exciting results on melanoma (see separate story today).
Ridaforolimus improves PFS in saracomas
Merck and ARIAD Pharmaceuticals (Nasdaq: ARIA) presented detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze